An Independent Data Monitoring Committee (IDMC) has recommended that the Phase 3 COMET-ICE trial, evaluating VIR-7831 (GSK4182136) as monotherapy for COVID-19, stop enrollment due to evidence of profound efficacy.
- The antibody treatment is being developed under a collaboration between Vir Biotechnology Inc's (NASDAQ: VIR) and GlaxoSmithKline Plc' (NYSE: GSK).
- The IDMC recommendation was based on an interim analysis of data from 583 patients, which demonstrated an 85% reduction in hospitalization or death in the VIR-7831 arm compared to placebo, the primary endpoint of the trial.
- VIR-7831 was well tolerated. The trial remains ongoing and blinded, with patients continuing to be followed for 24 weeks.
- Additionally, the companies said a new laboratory study showed the therapy, VIR-7831, was equally effective against the UK, South African, and Brazilian variants of the virus.
- Based on the findings, VIR and GSK now plan to seek emergency use authorization (EUA) for the COVID-19 antibody therapy.
- Last week, IDMC recommended closing enrollment in the VIR-7831 arm in NIH-sponsored ACTIV Program Phase 3 trial in hospitalized adults with COVID-19.
- Sensitivity analyses of the available data raised concerns about the magnitude of potential benefit.
- Price Action: VIR shares are trading 38.6% higher at 65, while GSK shares are 0.06% lower at $35.58 in premarket trading on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in